

3rd Vaccine Global Congress Programme

Sunday December 7, 2008		
Plenary session 1 - Setting the scene Chair: Shan Lu		
	Ray Spier	Welcome
11.00 - 11.10	Adel Mahmoud Princeton University, USA	Future of Vaccine Discovery
11.45 - 12.10	Hiroshi Kiyono University of Tokyo, Japan	Development of Self-Administrative Vaccine by MucoRice™ System
12.10 - 12.35	Raymond Welsh University of Massachusetts Medical School, USA	Pathogenic epitopes, heterologous immunity, and vaccine design
12.35 - 1.00	Mark K. Sliifka Oregon Health & Science University, USA	Duration of Immunity Following Vaccination: How Long it Can Last and How We Can Make it Better
1.00 - 2.00	Lunch	
Plenary session 2 - Major Infectious Disease Targets Chair: Shan Lu		
2.00 - 2.10	Elizabeth Adams NIAID, USA	Oral 1 - The Reiterative Discovery Process – HIV Vaccine Prevention Research Moving Forward Post The STEP Trial
2.10 - 2.35	Shan Lu University of Massachusetts Medical School, USA	Developing HIV Vaccines With Protective Antibody Responses
2.35 - 3.00	Adrian Hill The Jenner Institute, UK	New Vectored Vaccines for Malaria
3.00 - 3.25	Michael J. Brennan Aeras Global TB Vaccine Foundation, USA	TB Vaccine Development
3.25 - 4.00	<i>Exhibit hall and Coffee</i>	
3.30 - 4.00	<i>Poster Session</i>	<i>Human Vaccines Infectious Disease</i> <i>Human Vaccines Non Infectious Disease</i>
Plenary session 3 - Non-traditional vaccines Chair: Rino Rappouli		
4.00 - 4.25	Annie de Groot EpiVax Inc., USA	Computer-driven Vaccine Design: From Concept to Reality

4.25 – 4.50	Polly Gregor Memorial Sloan-Kettering Cancer Center, USA	Of Mice and Men (and Dogs): Clinical Development of Xenogeneic DNA Vaccines for Cancer.
4.50 - 5.00	Eric Huang University of California USA	Oral 2 - Acne Vaccines Targeting P. acnes Virulent Factors
5.00 - 5.10	Marcus Hoerer MediGene AG, Germany	Oral 3 - Development of AAV as Potent B-cell Vaccine Directed Against Human IgE for the Treatment of Severe Allergic Asthma
5.10 - 5.20	William Decker University of Texas MD Anderson Cancer Centre, USA	Oral 4 - Th-1 Immunity is Regulated by Dendritic Cell Comparison of MHC Class I and Class II Antigens: Implications for Successful Immunotherapy of Neoplasia
5.20 - 5.30	Philippe Leff National Institute of Psychiatry, Mexico	Oral 5 - Preclinical Studies On The Generation of Conjugated Vaccines for Addictive Drugs
5.30 - 7.30	<i>Opening reception - Poster & Exhibit hall</i>	

Monday December 8, 2008		
Plenary sessions 4 – Adjuvants		
Chair: Hiroshi Kiyono		
8.30 - 8.55	Kate A. Fitzgerald University of Massachusetts Medical School, USA	Pattern Recognition Receptors and the Adjuvant Response
8.55 - 9.20	Dennis Klinman NCI-Frederick, USA	Use of CpG Oligonucleotides as a Vaccine Adjuvant
9.20 - 9.30	Angelika Banzhoff Novartis, Germany	Oral 6 - An MF-59 Adjuvanted H5N1 Clade 1 Pre-pandemic Vaccine Confers Cross-reactive Antibodies to a Clade 2 H5N1 Virus Strain
9.30 - 9.40	Stephane Heijmans ResearchLink, Belgium	Oral 7 - AS03-Adjuvanted Prepandemic Influenza Vaccine: High Immunogenicity In The Elderly
9.40 - 9.50	Stephanie Eisenbarth Yale School of Medicine, USA	Oral 8 - Aluminum Hydroxide Adjuvants Activate the Immune System Through the Nalp3 Inflammasome
9.50 - 10.00	Eric Tartour Hopital Européen Georges Pompidou, France	Oral 9 - The Non Toxic B Subunit of Shiga Toxin Coupled to Various Antigens Elicits Mucosal Humoral and Cellular Immune Responses.
10.00 - 10.10	Marcin Kwissa Emory Vaccine Center, USA	Oral 10 - Adjuvating a DNA Vaccine With a TLR9 Ligand Plus Flt3 Ligand Results in Enhanced Cellular Immunity Against the Simian Immunodeficiency Virus
10.10 - 10.20	Bin Wang China Agricultural University, China	Oral 11 - Activation of MyD88 Dependent TLR 7/8 Pathway Leads to Cell Mediated Responses by Levamisole As A Potent Adjuvant for Therapeutic Vaccination Against HBV Infection

10.20 - 10.30	Wei Li University of Massachusetts Medical School, USA	Oral 12 - DNA Vaccine Prime Improved the Antigen-specific B Cell Memory and Longevity of B Cell Responses Against V Antigen of Yersinia Pestis in Mice
10.30 - 11.00	Exhibit hall and Coffee	
10.30 - 11.00	Poster Session	Adjuvants Delivery Systems Late Breaker Production & Other
Plenary sessions 5 - Delivery systems Chair: Peter Nara		
11.00 - 11.25	Bruce G. Weniger Centers for Disease Control and Prevention, USA	Vaccination Into or Onto the Skin: Advantages, Accomplishments, Actualizations, and Adumbrations of the Cutaneous Route
11.25 - 11.50	Dan Barouch Harvard Medical School, USA	Novel Adenovirus Vector-Based Vaccines for HIV-1
11.50 - 12.00	Julia Hurwitz St. Jude Children's Research Hospital USA	Oral 13 - Development of Sendai Virus-based Vaccines to Prevent Pediatric Respiratory Virus Infections
12.00 - 12.10	Tina Villar Intercell USA Inc	Oral 14 - Field Efficacy Results From a Field Trial Show a Patch Containing Heat Labile Enterotoxin from Escherichia coli (LT) Protects Against Travelers' Diarrhea
12.10 - 12.20	David Chang, University of Queensland, Australia	Oral 15 - West Nile virus DNA Vaccine Producing Single Round Infectious Particles Protects Mice From Lethal Encephalitis and Induce Virus-neutralising Antibodies in Horses
12.20 - 12.30	Brian Livingston, Ichor Medical Systems, USA	Oral 16 - Electroporation Mediated DNA Immunization: Comparative Performance Versus Classical Vaccine Approaches and Transition to Human Clinical Testing
12.30 - 2.15	Lunch	
12.30 - 1.30	Poster Session	Adjuvants Delivery Systems Late Breaker Production Other
1.30 - 2.00	ISV Business Meeting Harbor Ballroom	
Plenary sessions 6 - ISV President presentation Chair: Ray Spier		
2.15 - 3.15	Gregory A. Poland Mayo Vaccine Research Group, USA	Influenza Immunization of Health Care Workers: A Patient Safety Imperative

ISV selected abstract presentation		
3.15 - 3.25	Jan Pravsgaard Christensen University of Copenhagen, Denmark	Oral 17 - Improved immunogenicity of Adenoviral Vaccines: Impact of Tethering the Vaccine Antigen to MHC-class II Associated Invariant Chain
3.25 - 3.35	Indresh Srivastava Novartis Vaccines, USA	Oral 18 - Toward the Development of a SARS Vaccine
3.35 - 3.45	Mart Ustav FIT Biotech Oy Eesti AS, Estonia	Oral 19 - Development of the DNA Plasmid Based Genetic Vaccine Vectors, Which Use Segregation/Partitioning Functions of the Episomally Replicating DNA Viruses.
3.45 - 3.55	Vidya Arankalle (absent) National Institute for Virology, India	Oral 20 - Development of recombinant G protein-based vaccine for Chandipura virus
3.55 - 4.30	Exhibit hall and Coffee	
4.00 - 4.30	Poster Session	Adjuvants, Delivery Systems Late Breaker Production Other
Breakout session 1 - Vaccine production and clinical use Harbor Ballroom 2 & 3 Chair: Bruce Weniger		
4.30 - 4.55	Rich Costantino USA	Stability of Vaccines
4.55 - 5.05	Stephan Zweig Clinisense Corporation, USA	Oral 21 - Vaccine Stability Monitoring Using the LifeTrack® Electronic Stability Monitor
5.05 - 5.15	Derek Gregg Vandalia Research, USA	Oral 22 - System and Process for Large-Scale DNA Vaccine Production by PCR
5.15 - 5.25	Denis Leclerc Laval University, Canada	Oral 23 - Development of an Universal Influenza A Vaccine Using an Innovative Plant Virus Based Platform
5.25 - 5.35	Hana El Sahly, Baylor College of Medicine, USA	Oral 24 - Phase 1, Double-Blinded, Placebo-Controlled, Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly
5.35 - 5.45	Derek Brown RTI International Research, USA	Oral 25 - Mother and Daughter Preferences and Willingness to Pay for HPV Vaccination
5.45 - 5.55	Mark Steinhoff Cincinnati Childrens Hospital Medical Center, USA	Oral 26 - Maternal Immunization: an Underutilized Strategy to Protect both Mothers and Infants
5.55 - 6.05	Cathy Panozzo Center for Disease Control and Prevention, USA	Oral 27 - Delayed Onset and Diminished Magnitude of Rotavirus Activity--United States, November 2007-May 2008

Breakout session 2 - Late Breakers Abstracts – 1
Harbor Ballroom 1
Chair: Bob Chen

4.30 - 4.40	Jan ter Meulen Merck & Co, USA	Oral 28 - Modeling of a Highly Conserved Influenza HA2 Epitope for Vaccination and Evaluation in the Mouse Challenge Model.
4.40 - 4.50	Myra Widjoatmodjo Netherlands Vaccine Institute, The Netherlands	Oral 29 - A highly Attenuated Recombinant Human Respiratory Syncytial Virus Lacking the G Protein Confers Long Time Protection Against RSV Infection in Cotton Rats.
4.50 - 5.00	Maryann Giel-Moloney Acambis, USA	Oral 30 - RepliVax®: New Replication-Defective Flavivirus Vaccines and Vectors for Non-Flavivirus Immunogens
5.00 - 5.10	De-Chu Tang Vaxin Inc, USA	Oral 31 - Non-replicating Adenovirus-Vectored Avian Influenza Vaccine as a Rapid-Response Tool for Mitigating a Pandemic
5.10 - 5.20	Eryu Wang University of Texas, USA	Oral 32 - Chimeric Alphavirus Vaccines for Western Equine Encephalitis
5.20 - 5.30	Dorothee Herlyn The Wistar Institute, USA	Oral 33 - Antigens Recognized by Cytotoxic and Helper T Lymphocytes with Vaccine Potential for Cancer Patients
5.30 - 5.40	Peter Rottier Utrecht University, The Netherlands	Oral 34 - A Genetically Attenuated Feline Coronavirus Vaccine: Protection Against Feline Infectious Peritonitis (FIP) by Cellular Rather Than by Virus-Neutralizing Immunity
5.40 - 5.50	Aalzen De Haan The Netherlands	Oral 35 - Fusion Inactivation of H5N1 Whole Inactivated Virus (WIV) Vaccine Does Not Compromise its Superior Immunogenicity.
5.50 - 6.00	Cristina Nazarov Uniformed Services University, USA	Oral 36 - Down-Regulation of Influenza Viral Vaccination by CD4+25hi T-Regulatory Cells

Coaches depart from D St. entrance of the Westin Waterfront (concourse level) at 7.00pm

Tuesday December 9, 2008

Plenary session 7 - Novel Bacterial Vaccines
Chair: Jan ter Meulen

8.30 - 8.55	Rino Rappuoli Novartis Vaccines and Diagnostics, Italy	Vaccines: An Health Insurance of the 21st century
8.55 - 9.20	John W. Shiver Merck and Co Inc., USA	Development of a Novel Staphylococcus Aureus Vaccine Based on a Conserved Protein Antigen
9.20 - 9.45	Jennifer Schranz Wyeth, USA	Pneumococcal Conjugate Vaccines: What Do We Know and What Do We Need?
9.45 - 9.55	Carmen Giefing Intercell AG, Austria	Oral 37 - Development of a Full Coverage Pneumococcal Vaccine Comprising Highly Conserved Proteins With a Crucial Function in the Bacterial Life Cycle
9.55 - 10.05	Peter Dull	Oral 38 - A Phase III Head-to-Head Comparison of a

	Novartis, USA	Novel Quadrivalent Meningococcal Conjugate Vaccine, MenACWY-CRM, With the Licensed Meningococcal ACWY Conjugate Vaccine, Menactra®, in Healthy Subjects 11-55 Years of Age
10.05 - 10.15	Yongqun He University of Michigan, USA	Oral 39 - Vaxign: a Web-based Vaccine Target Design Program for Reverse Vaccinology
10:15-10:25	Daniel Scott Wyeth, USA	Oral 40 - Safety & Immunologic Non-inferiority of 13-valent Pneumococcal Conjugate Vaccine Compared to 7-valent Pneumococcal Conjugate Vaccine Given with Routine Vaccines in Healthy Infants
10.25 - 11.00	Exhibit hall and Coffee	
10.30 - 11.00	Poster session	Veterinary Vaccines Immunology/Animal Models
Plenary session 8 - Emerging Infectious Disease & Biodefense Harbor Ballroom 2 & 3 Chair: John Oxford & Alan Barrett		
11.00 - 11.25	Alan Barrett University of Texas Medical Branch, USA	Characterization of Type-specific and Dengue Complex Antigenic Sites on the Envelope Protein Domain III of Dengue Viruses
11.25 - 11.50	John S. Oxford Retroscreen Virology Ltd, UK	The Ferret and Human Models for Influenza Vaccine Evaluation
11.50 - 12.00	Trudy Morrison University of Massachusetts Medical School, USA	Oral 41 - The Immunogenicity and Efficacy of a Virus-like Particle Vaccine Candidate against Respiratory Syncytial Virus in Mice
12.00 - 12.10	Nicolas Sabarth, Baxter Innovations GmbH, Austria	Oral 42 - Induction of Longitudinal Cross-Clade Anti-H5N1 Immunity and Protection by Homologous and Heterologous Prime-Boost Immunization Regimes with Whole Virus H5N1 Influenza Candidate vaccines
12.10 - 12.20	George Bettinger University of Texas Medical Branch, USA	Oral 43 - Genetic and Clinical Evaluation of MP-12: a live Attenuated Vaccine for Rift Valley Fever Virus (RVFV)
12.20 - 12.30	Igor Lukashevich Institute of Human Virology, USA	Oral 44 - A ML29 Reassortant Lassa Fever Vaccine is Safe and Induces Broad Cell-Mediated Protective Immune Responses in Experimental Animals
12.30 - 12.40	Hana El Sahly Baylor College of Medicine, USA	Oral 45 - Phase 1, Double-Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Reactogenicity of Francisella tularensis Live Vaccine Strain (LVS) Administered by the Scarification or Subcutaneous Route
Breakout session 3 - Late Breaker Abstracts – 2 Harbor Ballroom 1 Chair: John Shiver		
11.00 - 11.10	Harry Hull HF Hull & Associates, USA	Oral 46 - Strategies for Achieving Efficient Implementation of an Expanded ACIP Recommendation for Influenza Vaccination of School-aged Children

11.10 - 11.20	Benoit Dervaux CRESGE, France	Oral 47 - The value of Information When Considering Introduction of a New Vaccine in the Immunisation Schedule: A Conjoint Analysis Conducted in Europe
11.20 - 11.30	David Klatzmann (absent) UMR 7087 UPMC-CNRS, France	Oral 48 - Rational Design and Standardized Evaluation of Novel Genetic Vaccines
11.30 - 11.40	Mauro Pistello University of Pisa, Italy	Oral 49 - Prime-Boost Vaccination with DNA-Transduced Autologous Lymphocytes Protects Against Fully Virulent Homologous Challenge in the Feline Immunodeficiency Virus AIDS Model
11.40 - 11.50	Tomonori Nochi University of Tokyo, Japan	Oral 50 - Exploit of Nanogel as a Novel Carrier of Mucosal Vaccine: Nanogel Mucosal Vaccine Effectively Induces Protective Immunity Against Botulinum Toxin
11.50 - 12.00	Wil Landman Animal Health Service, The Netherlands	Oral 51 - Vaccination of Broiler Chickens with Dry Powder Vaccines as an Alternative for Liquid Spray and Aerosol Vaccination
12.00 - 12.10	Dominique Schols Rega Institute for Medical Research, Belgium	Oral 52 - HIV-1 Resistance Towards CADA-induced CD4 Receptor-Targeted Inhibition is Associated with Increased Sensitivity to Neutralizing Antibodies.
12.10 - 12.20	Valentina Feodorova Saratov State University, Russia	Oral 53 - Yersinia pestis Live Vaccine with Improved Characteristics
12.20 - 12.30	Julie Milstien University of Maryland School of Medicine, USA	Oral 54 - Challenges and Potential Solutions to Innovative Vaccine Development in Developing Countries
12.30 - 2.00	Exhibit hall and Lunch	
12.45 - 1.15	Poster session	Veterinary Vaccines Immunology/Animal Models
Plenary 9 - Vaccine Policy and public health issues Chair: Ray Spier		
2.00 -2.25	Dack Dalrymple Dalrymple & Associates, LLC, USA	Current & Future U.S. Government Funding for Vaccine R&D and Acquisition
2.25 - 2.50	Bob Chen Centers for Disease Control and Prevention, USA	Enhancing Vaccine Safety Assessment During Vaccine Development: Some Modest Proposals
2.50 - 3.15	Jon Andrus Pan American Health Organization, USA	Implementing Vaccination Programs in Developing Countries
3.15 - 3.40	Peter Nara Biological Mimetics Inc, USA	Improving on Mother Nature's Immunogenicity
3.40 - 4.05	Ray Spier	Dealing with Ethical Issues in the Area of Vaccines and Vaccination
Ray Spier and Shan Lu		Closing Summary